Rudolph M Navari

Summary

Affiliation: University of Notre Dame
Country: USA

Publications

  1. doi request reprint Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial
    Rudolph M Navari
    Indiana University School of Medicine South Bend, South Bend, IN, USA
    J Support Oncol 9:188-95. 2011
  2. doi request reprint The current status of the use of palonosetron
    Rudolph Navari
    Indiana University School of Medicine South Bend Medicine, 1234 Notre Dame Avenue, South Bend, Indiana, 46617, USA
    Expert Opin Pharmacother 14:1281-4. 2013
  3. doi request reprint The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Rudolph M Navari
    Indiana University School of Medicine South Bend, 1234 Notre Dame Avenue, South Bend, IN, 46617, USA
    Support Care Cancer 21:1655-63. 2013
  4. doi request reprint Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents
    Rudolph M Navari
    Indiana University School of Medicine, 1234 Notre Dame Avenue, South Bend, IN 46617, USA
    Drugs 73:249-62. 2013
  5. ncbi request reprint A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
    Rudolph M Navari
    Notre Dame Cancer Institute, University of Notre Dame, 224 Raclin Carmichael Hall, Notre Dame, IN 46556, USA
    Support Care Cancer 15:1285-91. 2007
  6. ncbi request reprint Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Rudolph M Navari
    Indiana University School of Medicine, South Bend, IN, USA
    Expert Opin Investig Drugs 16:1977-85. 2007
  7. ncbi request reprint Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, IN 46556, USA
    Breast Cancer Res Treat 112:197-201. 2008
  8. doi request reprint Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, South Bend, IN 46617, USA
    Expert Rev Anticancer Ther 8:1733-42. 2008
  9. ncbi request reprint Antiemetic control: toward a new standard of care for emetogenic chemotherapy
    Rudolph M Navari
    University of Notre Dame, Walther Cancer Research Center, South Bend, IN 46617, USA
    Expert Opin Pharmacother 10:629-44. 2009
  10. doi request reprint Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments
    Rudolph M Navari
    Department of Medicine, Indiana University School of Medicine, South Bend, USA
    Drugs 69:515-33. 2009

Collaborators

Detail Information

Publications30

  1. doi request reprint Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial
    Rudolph M Navari
    Indiana University School of Medicine South Bend, South Bend, IN, USA
    J Support Oncol 9:188-95. 2011
    ..The purpose of the study was to compare the effectiveness of olanzapine (OLN) and aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy...
  2. doi request reprint The current status of the use of palonosetron
    Rudolph Navari
    Indiana University School of Medicine South Bend Medicine, 1234 Notre Dame Avenue, South Bend, Indiana, 46617, USA
    Expert Opin Pharmacother 14:1281-4. 2013
    ..Due to its efficacy in controlling both acute and delayed CINV, palonosetron may be very effective in the clinical settings of multiple-day chemotherapy and bone marrow transplantation...
  3. doi request reprint The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Rudolph M Navari
    Indiana University School of Medicine South Bend, 1234 Notre Dame Avenue, South Bend, IN, 46617, USA
    Support Care Cancer 21:1655-63. 2013
    ..Olanzapine may also be an effective rescue medication for patients who develop breakthrough CINV despite having received guideline-directed CINV prophylaxis...
  4. doi request reprint Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents
    Rudolph M Navari
    Indiana University School of Medicine, 1234 Notre Dame Avenue, South Bend, IN 46617, USA
    Drugs 73:249-62. 2013
    ..Additional studies are necessary for the control of nausea and for the control of CINV in the clinical settings of multiple-day chemotherapy and bone marrow transplantation...
  5. ncbi request reprint A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
    Rudolph M Navari
    Notre Dame Cancer Institute, University of Notre Dame, 224 Raclin Carmichael Hall, Notre Dame, IN 46556, USA
    Support Care Cancer 15:1285-91. 2007
    ....
  6. ncbi request reprint Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Rudolph M Navari
    Indiana University School of Medicine, South Bend, IN, USA
    Expert Opin Investig Drugs 16:1977-85. 2007
    ..Further study is needed to clarify the use of fosaprepitant for the prevention of CINV, and to clarify optimal dosing regimens that may be appropriate substitutes for oral aprepitant...
  7. ncbi request reprint Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, IN 46556, USA
    Breast Cancer Res Treat 112:197-201. 2008
    ....
  8. doi request reprint Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, South Bend, IN 46617, USA
    Expert Rev Anticancer Ther 8:1733-42. 2008
    ..Further study is needed to clarify the utility of fosaprepitant in the prevention of CINV and to clarify optimal dosing regimens that may be appropriate substitutes for oral aprepitant...
  9. ncbi request reprint Antiemetic control: toward a new standard of care for emetogenic chemotherapy
    Rudolph M Navari
    University of Notre Dame, Walther Cancer Research Center, South Bend, IN 46617, USA
    Expert Opin Pharmacother 10:629-44. 2009
    ....
  10. doi request reprint Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments
    Rudolph M Navari
    Department of Medicine, Indiana University School of Medicine, South Bend, USA
    Drugs 69:515-33. 2009
    ..g. olanzapine, gabapentin, cannabinoids) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation...
  11. doi request reprint Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial
    Rudolph M Navari
    Department of Medicine, Indiana University School of Medicine South Bend, IN, USA
    Support Care Cancer 18:951-6. 2010
    ..The purpose of the study was to determine the effectiveness of megestrol acetate (MA) and olanzapine (OLN) for the treatment of cancer-related anorexia (CRA)...
  12. doi request reprint Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist
    Rudolph M Navari
    Indiana University School of Medicine South Bend, Walther Cancer Research Center, University Notre Dame, South Bend, IN 46617, USA
    Expert Opin Drug Metab Toxicol 5:1577-86. 2009
    ..The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV...
  13. doi request reprint Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer
    Rudolph M Navari
    Indiana University School of Medicine South Bend, 1234 North Notre Dame Avenue, South Bend, IN 46617 1404, USA
    Future Oncol 6:1073-84. 2010
    ..Owing to its efficacy in controlling both acute and delayed CINV, palonosetron may be very effective in the clinical setting of multiple-day chemotherapy and bone marrow transplantation...
  14. ncbi request reprint Prevention of emesis from multiple-day and high-dose chemotherapy regimens
    Rudolph M Navari
    Indiana University School of Medicine South Bend, and the Notre Dame Cancer Institute, University of Notre Dame, South Bend, IN 46617, USA
    J Natl Compr Canc Netw 5:51-9. 2007
    ..These agents have high potential for preventing CINV in patients undergoing multiple-day chemotherapy. This article proposes recommendations for their use in clinical trials and in practice...
  15. ncbi request reprint Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists
    Rudolph M Navari
    College of Science and Walther Cancer Research Center, University of Notre Dame, Notre Dame, IN 46556 5670, USA
    Ann Pharmacother 37:1276-86. 2003
    ..To review the electrocardiographic (ECG) and cardiovascular effects of 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonists preclinically, in healthy volunteers, and in patients undergoing chemotherapy or surgery...
  16. ncbi request reprint Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana 46556, USA
    J Support Oncol 1:89-103. 2003
    ....
  17. ncbi request reprint Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting
    Rudolph M Navari
    College of Science, Walther Cancer Research Center, 250 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA
    Expert Rev Anticancer Ther 4:715-24. 2004
    ..Future studies may consider the use of aprepitant with current and other new agents in moderately and highly emetogenic chemotherapy, as well in the clinical settings of multiple-day chemotherapy and bone marrow transplantation...
  18. ncbi request reprint Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials
    Rudolph M Navari
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana 46556, USA
    Cancer Invest 22:569-76. 2004
    ..Future studies may explore the use of aprepitant and other NK-1s in moderately and highly emetogenic chemotherapy, as well in the clinical settings of multiple-day chemotherapy and bone marrow transplantation...
  19. ncbi request reprint A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study
    Rudolph M Navari
    Walter Cancer Research Center, University of Notre Dame, 250 Nieuwland Science Hall, Notre Dame, IN 46556, USA
    Support Care Cancer 13:529-34. 2005
    ..Olanzapine is safe and highly effective in controlling acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly and moderately emetogenic chemotherapy...
  20. ncbi request reprint Emerging drugs for chemotherapy-induced emesis
    Rudolph M Navari
    University of Notre Dame, Notre Dame, IN 46556, USA
    Expert Opin Emerg Drugs 11:137-51. 2006
    ....
  21. ncbi request reprint Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist
    Rudolph M Navari
    Indiana University School of Medicine, Notre Dame Cancer Institute, South Bend, IN 46617, USA
    Future Oncol 2:591-602. 2006
    ..Future studies may consider the use of palonosetron with current and other new agents and in other clinical settings, such as bone marrow transplantation and radiation therapy...
  22. ncbi request reprint A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study
    Steven D Passik
    Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, Indiana, USA
    Cancer Invest 22:383-8. 2004
    ..Therefore, olanzapine may be an effective agent for the prevention of chemotherapy-induced DE. A phase II trial is underway...
  23. ncbi request reprint Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities
    Rudolph M Navari
    Indiana University School of Medicine, South Bend, 100 Raclin Carmichael Hall, South Bend, IN 46617, USA
    Curr Opin Investig Drugs 9:774-85. 2008
    ..Casopitant was previously being developed for the treatment of overactive bladder; however, in September 2007, this indication was no longer listed on the company's product pipeline...
  24. ncbi request reprint The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice
    Mark A Suckow
    Walther Cancer Center, 400 Freimann Life Science Center, University of Notre Dame, Notre Dame, IN 46556, USA
    Cancer Lett 209:165-9. 2004
    ..Tumors from drug-treated mice were also more dysplastic and invasive than those from untreated mice. These findings have implications for the use of ranolazine in patients with a history of malignant neoplasms or adenomatous polyps...
  25. pmc An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia
    Francis J Castellino
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA
    Blood 117:283-9. 2011
    ..This suggests that proteases generated as a result of factor VIIa/TF-mediated thrombin generation play a mechanistic role in the enhanced lethality seen under very low PC conditions in an endotoxemia model in mice...
  26. ncbi request reprint Cathepsin E is a specific marker of dysplasia in APC mouse intestine
    Lizette Busquets
    Walther Cancer Center, Notre Dame, IN 46556, USA
    Tumour Biol 27:36-42. 2006
    ..These results authenticate the relationship between transcript abundance and protein levels in transformed tissue and suggest potential utility for catE as a marker for the inception and progression of intestinal cancers...
  27. ncbi request reprint Symptomatic treatment of infections in patients with advanced cancer receiving hospice care
    Raquel E Reinbolt
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana 46556, USA
    J Pain Symptom Manage 30:175-82. 2005
    ..Treatment guidelines are proposed emphasizing the importance of patient preferences and the use of symptom control as the major indication for the use of antimicrobials in this patient population...
  28. ncbi request reprint Antimicrobial use in patients with advanced cancer receiving hospice care
    Patrick H White
    Walther Cancer Research Center, University of Notre Dame, Notre Dame, IN 46556, USA
    J Pain Symptom Manage 25:438-43. 2003
    ..Symptom control may be the major indication for antimicrobial use for patients receiving hospice and palliative care...
  29. ncbi request reprint New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations
    Edward B Rubenstein
    Division of Medical and Scientific Affairs, MGI Pharma, Bloomington, Minnesota 55437, USA
    Cancer J 12:341-7. 2006
    ..Investigations into the pharmacogenomics of CINV may someday be able to aid in the identification of high risk patients and patients unlikely to respond to conventional therapies...
  30. ncbi request reprint Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869
    Simon Van Belle
    Oncologisch Centrum, Universitair Ziekenhuis, Gent, Belgium
    Cancer 94:3032-41. 2002
    ....